Annual Report 2011 Active Biotech AB (publ)
LUND, SWEDEN, Apr 17, 2012 (Menafn - MARKETWIRE via COMTEX) --Active Biotech's Annual Report 2011 (in Swedish) is now availablefor downloadat www.activebiotech.com.
The Annual Report will only be digitally distributed.
Lund, April 17, 2012
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
Active Biotech AB (nasdaq omx nordic:ACTI) is a biotechnology companywith focus on autoimmune/inflammatory diseases and cancer. Projects inor enteringpivotal phase are laquinimod, an orally administered smallmolecule with uniqueimmunomodulatory properties for the treatment ofmultiple sclerosis, TASQ forprostate cancer as well as ANYARA foruse in cancer targeted therapy, primarilyof renal cell cancer. Inaddition, laquinimod is in Phase II development forCrohn's andLupus. Further projects in clinical development comprise thetwoorally administered compounds, 57-57 for Systemic Sclerosis andRhuDex(R) for RA. Please visit http://www.activebiotech.com for moreinformation.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: 46 46 19 20 00
Fax: 46 46 19 11 00
Active Biotech is obligated to publish the information contained inthis pressrelease in accordance with the Swedish Securities MarketAct. This informationwas provided to the media for publication onApril 17, 2012, at 10:00 a.m.
Annual Report 2011 Active Biotech AB (publ):http://hugin.info/1002/R/1602829/506506.pdf
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrantsthat: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible forthe content, accuracy and originality of the informationcontained therein.
Source: Active Biotech via Thomson Reuters ONE [HUG#1602829]
For further information, please contact:
Hans Kolam
CFO
Tel 46 (0)46 19 20 44
SOURCE: Active Biotech
Copyright 2012 Marketwire, Inc., All rights reserved.
